Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
TRAMADOL HYDROCHLORIDE
MEDA Pharmaceuticals Ltd
100mg/2ml Mg/Ml
Solution for Injection
2006-04-28
PART II SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Zamadol 100mg/2ml Solution for Injection or Infusion 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Tramadol hydrochloride 50 mg/ml of injection solution (100 mg per 2ml ampoule) _For a full list of excipients see section 6.1_ 3 PHARMACEUTICAL FORM Solution for Injection or Infusion. Clear, colourless sterile solution. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS For the treatment and prevention of severe pain. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION The injection is for parenteral administration either intramuscularly, by slow intravenous injection or, when diluted in solution, by infusion or patient controlled analgesia. As with all analgesic drugs the dosing of Zamadol Injection should be adjusted depending on the severity of the pain and the individual clinical response of the patient. ADULTS: A dose of 50 or 100 mg 4-6 hourly is usually required. Intravenous injections must be given slowly over 2-3 minutes. In post-operative pain, an initial bolus of 100 mg is administered. For the 60 minutes following this initial bolus, 50 mg doses may be given every 10-20 minutes up to a total dose of 250 mg including the initial bolus. Subsequent doses should be 50 or 100 mg 4-6 hourly up to a total daily dose of 400 mg. A total parenteral daily dose of 400 mg should not be exceeded except in special circumstances. ELDERLY PATIENTS: Dosing as for adults but it should be noted that in a study in elderly volunteers (aged over 75 years) the elimination half-life for orally administered tramadol was increased by 17%. PATIENTS WITH RENAL INSUFFICIENCY/RENAL DIALYSIS As the elimination of tramadol may be prolonged in patients with renal impairment, the usual initial adult doses should be employed, b Read the complete document